Under legislation to be introduced in the U.S. Senate, makers of generic drugs would gain the right to market generic versions of biopharmaceutical medicines. The legislation would create a pathway for the FDA to approve generic treatments made through biotechnology. According to analysts, competition from lower-cost generics may cut biopharmaceutical drug prices by a third. Generic companies are targeting drugs whose patents have already expired or are set to expire. Companies such as Barr...